Wird geladen...

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

IMPORTANCE: Treatment with atezolizumab plus bevacizumab may prolong overall survival among patients with unresectable hepatocellular carcinoma. However, to our knowledge, the cost-effectiveness of using this high-priced therapy for this indication is currently unknown. OBJECTIVE: To evaluate the co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Netw Open
Hauptverfasser: Su, Dan, Wu, Bin, Shi, Lizheng
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2021
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905498/
https://ncbi.nlm.nih.gov/pubmed/33625508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.0037
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!